Medical Editor: John P. Cunha, DO, FACOEP
Adenocard IV (adenosine) Injection is an antiarrhythmic drug used to treat paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). Adenocard IV is available in generic form. Common side effects of Adenocard IV include:
- facial flushing,
- shortness of breath,
- chest pressure,
- chest pain,
- low blood pressure (hypotension),
- head pressure,
- tingling in arms,
- blurred vision,
- burning sensation,
- heaviness in arms,
- neck and back pain,
- metallic taste in mouth,
- tightness in throat, and
- pressure in groin.
The initial adult dose of Adenocard IV is 6 mg given as a rapid intravenous bolus (administered over a 1-2 second period). If the first dose does not result in elimination of the supraventricular tachycardia within 1-2 minutes, 12 mg should be given as a rapid intravenous bolus. Adenocard IV may interact with digoxin, verapamil, digitalis, caffeine, theophylline, dipyridamole, or carbamazepine. Tell your doctor all medications and supplements you use. During pregnancy, Adenocard IV should be used only if prescribed. Consult your doctor before breastfeeding.
Our Adenocard IV (adenosine) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The following reactions were reported with intravenous Adenocard (adenosine injection) used in controlled U.S. clinical trials. The placebo group had a less than 1% rate of all of these reactions.
Shortness of breath/dyspnea (12%), chest pressure (7%), hyperventilation, head pressure (less than 1%).
Central Nervous System
Nausea (3%), metallic taste, tightness in throat, pressure in groin (less than 1%).
Post Marketing Experience
The following adverse events have been reported from marketing experience with Adenocard. Because these events are reported voluntarily from a population of uncertain size, are associated with concomitant diseases and multiple drug therapies and surgical procedures, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these events in labeling are typically based on one or more of the following factors: (1) seriousness of the event, (2) frequency of the reporting, (3) strength of causal connection to the drug, or a combination of these factors.
Central Nervous System
Seizure activity, including tonic clonic (grand mal) seizures, and loss of consciousness.
Read the entire FDA prescribing information for Adenocard (Adenosine)
© Adenocard Patient Information is supplied by Cerner Multum, Inc. and Adenocard Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.